Clinical Trial Update: Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing weekly versus every-three-weeks docetaxel plus cisplatin in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Gachon University Gil Medical Center | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED